Do I need to take bevacizumab when taking osimertinib/osimertinib?

Concurrent use of osimertinib/ and bevacizumab is generally not required in the treatment of EGFR (epidermal growth factor receptor) mutation-positive advanced non-small cell lung cancer (NSCLC). Bevacizumab is an immune checkpoint inhibitor used to treat some patients with NSCLC. However, targeted therapies such as osimertinib/osimertinib are usually preferred for EGFRmutated NSCLC. In most cases, osimertinib is used as the first-line treatment option, while bevacizumab is often used as a subsequent treatment option. Therefore, concomitant use of bevacizumab is generally not required when using osimertinib/osimertinib. Treatment plans should be individually formulated based on the patient's specific situation and disease characteristics, and it is recommended that treatment decisions be made under the guidance of a doctor.